John D. Mendlein
2016
In 2016, John D. Mendlein earned a total compensation of $1.6M as Chief Executive Officer and Director at aTYR PHARMA, a 60% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $192,933 |
|---|---|
| Option Awards | $865,816 |
| Salary | $494,700 |
| Other | $16,028 |
| Total | $1,569,477 |
Mendlein received $865.8K in option awards, accounting for 55% of the total pay in 2016.
Mendlein also received $192.9K in non-equity incentive plan, $494.7K in salary and $16K in other compensation.
Rankings
In 2016, John D. Mendlein's compensation ranked 6,039th out of 14,075 executives tracked by ExecPay. In other words, Mendlein earned more than 57.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,039 out of 14,075 | 57th |
Division Manufacturing | 2,201 out of 5,489 | 60th |
Major group Chemicals And Allied Products | 719 out of 1,895 | 62nd |
Industry group Drugs | 541 out of 1,538 | 65th |
Industry Biological Products, Except Diagnostic Substances | 102 out of 279 | 63rd |
Source: SEC filing on March 30, 2017.
Mendlein's colleagues
We found two more compensation records of executives who worked with John D. Mendlein at aTYR PHARMA in 2016.